Kinetic mechanism for the interaction of Hirulog with thrombin
- PMID: 7993908
- DOI: 10.1021/bi00253a020
Kinetic mechanism for the interaction of Hirulog with thrombin
Abstract
Hirulog (D-FPRPGGGGDGDFEEIPEEYL) is a bivalent inhibitor of thrombin consisting of a moiety (D-FPRP) that binds to the active-site cleft and a hirudin-like C-terminal region (DGDFEEIPEEYL) that binds to the positively charged surface groove of thrombin known as the anion-binding exosite. The formation of the thrombin-Hirulog complex was studied using steady-state and rapid kinetics at 37 degrees C. The inhibition constant for Hirulog was found to be 1.9 nM. Hirulog was slowly degraded by thrombin with a kcat value of 0.01 s-1. The formation of the complex resulted in an enhancement of 44% in the intrinsic fluorescence of thrombin. The kinetics of the increase in thrombin fluorescence were described by a double-exponential decay. The dependence of the rate constant for the fast phase on the concentration of Hirulog could be described by the Michaelis-Menten equation with Km and kmax values of 0.75 +/- 0.12 microM and 325 +/- 17 s-1. The data were consistent with a mechanism in which the C-terminal region of Hirulog binds to the anion-binding exosite with a dissociation constant of 0.75 microM in the first step, followed by two intramolecular steps with rate constants of about 300 and 30 s-1. A C-terminal fragment of hirudin was found to compete in the first step confirming that this process corresponded to the binding of the hirudin-like C-terminus of Hirulog to the anion-binding exosite.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Hirulog-1 and -B2 thrombin specificity.Biochem J. 1992 Oct 15;287 ( Pt 2)(Pt 2):663-4. doi: 10.1042/bj2870663. Biochem J. 1992. PMID: 1445227 Free PMC article. No abstract available.
-
Thrombin-specific inhibition by and slow cleavage of hirulog-1.Biochem J. 1992 May 1;283 ( Pt 3)(Pt 3):737-43. doi: 10.1042/bj2830737. Biochem J. 1992. PMID: 1290488 Free PMC article.
-
Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.Biochem J. 1992 May 1;283 ( Pt 3)(Pt 3):893-7. doi: 10.1042/bj2830893. Biochem J. 1992. PMID: 1590777 Free PMC article.
-
Thrombin inhibition by hirudin: how hirudin inhibits thrombin.Haemostasis. 1991;21 Suppl 1:27-31. doi: 10.1159/000216259. Haemostasis. 1991. PMID: 1894193 Review.
-
Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor.Adv Exp Med Biol. 1993;340:227-36. doi: 10.1007/978-1-4899-2418-6_20. Adv Exp Med Biol. 1993. PMID: 8154339 Review. No abstract available.
Cited by
-
Bivalirudin: a review of its potential place in the management of acute coronary syndromes.Drugs. 2002;62(5):841-70. doi: 10.2165/00003495-200262050-00008. Drugs. 2002. PMID: 11929334 Review.
-
New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?Molecules. 2016 Feb 27;21(3):284. doi: 10.3390/molecules21030284. Molecules. 2016. PMID: 26927051 Free PMC article. Review.
-
Bivalirudin in percutaneous coronary intervention.Vasc Health Risk Manag. 2006;2(4):357-63. doi: 10.2147/vhrm.2006.2.4.357. Vasc Health Risk Manag. 2006. PMID: 17323589 Free PMC article. Review.
-
Direct thrombin inhibitors: pharmacology and application in intensive care medicine.Intensive Care Med. 2010 Jul;36(7):1127-37. doi: 10.1007/s00134-010-1888-3. Epub 2010 Apr 28. Intensive Care Med. 2010. PMID: 20425104 Review.
-
Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.Vasc Health Risk Manag. 2008;4(3):493-505. doi: 10.2147/vhrm.s2455. Vasc Health Risk Manag. 2008. PMID: 18827868 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources